Danvatirsen
- Generic Name
- Danvatirsen
- Drug Type
- Biotech
- CAS Number
- 1402357-06-5
- Unique Ingredient Identifier
- 31N550RD05
- Background
Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath